UMN Pharma Inc. announced consolidated and non-consolidated earnings results for the year ended December 31, 2014. For the full year, on consolidated basis, the company announced net sales of JPY 1,108.522 million against JPY 93.379 million a year ago. Operating loss was JPY 3,942.694 million against JPY 4,421.977 million a year ago. Loss before income taxes and minority interests was JPY 4,002.394 million against JPY 4,140.486 million a year ago. Net loss was JPY 3,961.233 million or JPY 452.34 per basic share against JPY 3,717.117 million or JPY 491.59 per basic share a year ago. Net cash provided by operating activities was JPY 314.665 million against net cash used in operating activities of JPY 3,578.459 million a year ago. Purchase of tangible fixed assets was JPY 5.004 million compared to JPY 3,894.139 million for the same period a year ago. Purchases of intangible fixed assets was JPY 3.306 million compared to JPY 425.671 million for the same period a year ago.

For the full year, on non-consolidated basis, the company announced net sales of JPY 1,108 million against JPY 92 million a year ago. Operating loss was JPY 2,861 million against JPY 3,301 million a year ago. Net loss was JPY 2,822 million or JPY 322.29 per basic share against JPY 3,207 million or JPY 424.14 per basic share a year ago.

The company provided earnings guidance for the full year ending December 31, 2015. For the full year ending December 31, 2015, the company expects to report net sales of JPY 5,224 million, operating loss of JPY 878 million, ordinary loss of JPY 1,025 million and net loss of JPY 1,033 million or JPY 108.14 per share.